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Assessment of the Psoriatic Transcriptome in
a Large Sample: Additional Regulated Genes
and Comparisons with In Vitro Models
Johann E. Gudjonsson1,4, Jun Ding2,4, Andrew Johnston1, Trilokraj Tejasvi1, Andrew M. Guzman1,
Rajan P. Nair1, John J. Voorhees1, Goncalo R. Abecasis2 and James T. Elder1,3
To further elucidate molecular alterations in psoriasis, we performed a gene expression study of 58 paired
lesional and uninvolved psoriatic and 64 control skin samples. Comparison of involved psoriatic (PP) and
normal (NN) skin identified 1,326 differentially regulated transcripts encoding 918 unique genes (549 up- and
369 downregulated), of which over 600 are to our knowledge previously unreported, including S100A7A, THRSP,
and ELOVL3. Strongly upregulated genes included SERPINB4, PI3, DEFB4, and several S100-family members.
Strongly downregulated genes included Wnt-inhibitory factor-1 (WIF1), b-cellulin (BTC), and CCL27. Enriched
gene ontology categories included immune response, defense response, and keratinocyte differentiation.
Biological processes regulating fatty acid and lipid metabolism were enriched in the down-regulated gene set.
Comparison of the psoriatic transcriptome to the transcriptomes of cytokine-stimulated cultured keratinocytes
(IL-17, IL-22, IL-1a, IFN-g, TNF-a, and OSM) showed surprisingly little overlap, with the cytokine-stimulated
keratinocyte expression representing only 2.5, 0.7, 1.5, 5.6, 5.0, and 1.9% of the lesional psoriatic dysregulated
transcriptome, respectively. This comprehensive analysis of differentially regulated transcripts in psoriasis
provides additional insight into the pathogenic mechanisms involved and emphasizes the need for more
complex yet tractable experimental models of psoriasis.
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INTRODUCTION
Psoriasis is a genetically determined chronic inflammatory
disease of the skin characterized by sharply demarcated scaly
red plaques commonly located on the extensor surfaces of the
skin. The most characteristic feature of psoriasis is marked
hyperproliferation and altered differentiation of the epider-
mis. Additionally, psoriasis has complex immunological,
biochemical, vascular, and neurological alterations. Psoriasis
has been shown to be immune-mediated as targeted
treatments against T-cells (Ellis et al., 1986) or principal
inflammatory mediators such as tumor necrosis factor-a
(TNF-a) (Gottlieb et al., 2003; Leonardi et al., 2003) lead to
near-complete remission of the disease. Recent genetic
association studies of psoriasis support this concept, but
suggest that the story is more complex, with variants in
genetic loci regulating barrier function (Zhang et al., 2009; de
Cid et al., 2009) and antimicrobial defenses (Hollox et al.,
2008) in addition to antigen presentation (Nair et al., 2006),
NF-kB signaling (Nair et al., 2009), and T-cell polarization
(Chang et al., 2008; Nair et al., 2009) all having a role in its
pathogenesis.
Earlier studies of the functional pathways involved in the
pathogenesis of psoriasis were limited to one or a few
genes or proteins at a time. Examples include transforming
growth factor-a (Elder et al., 1989), S100A7 (Madsen et al.,
1991), S100A8 and S100A9 (Kelly et al., 1989), protease
inhibitor-3 (PI3/elafin/skin-derived anti-leukoproteinase (SKALP))
(Schalkwijk et al., 1990), IFN-g (Bjerke et al., 1983), and
IL-8 (CXCL8) (Christophers et al., 1989). Recently, array-
based techniques that profile multiple genes at the same
time have become important methods to characterize mole-
cular alterations. The first array-based gene expression study
of psoriasis identified 159 genes in eight psoriasis patients
that were differentially regulated between uninvolved and
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lesional skin (Oestreicher et al., 2001). Likewise, a similar
study of 15 psoriasis patients identified a total of 177 genes
that differed in expression in lesional versus normal skin
(Bowcock et al., 2001). Another study of 15 atopic dermatitis
patients and 14 psoriasis patients identified 62 genes
upregulated in psoriatic as compared with that in atopic skin
(Nomura et al., 2003). More recent array-based studies have
indicated that over 1,000 genes may be differentially
regulated in psoriatic lesions as compared with that in
normal skin (Zhou et al., 2003; Haider et al., 2006). Interest-
ingly, a number of these genes are differentially expressed in
the lesional skin of psoriasis relative to that in chronic atopic
dermatitis, despite comparable epidermal hyperplasia in these
two settings (Nomura et al., 2003; de Jongh et al., 2005).
These studies provide a detailed but complex picture
of the gene expression events in lesional psoriatic skin. To aid
in the interpretation of such data, gene expression maps
based on cytokine stimulation of keratinocytes have recently
been published (Banno et al., 2004; Finelt et al., 2005; Gazel
et al., 2006; Bando et al., 2007; Mee et al., 2007; Haider
et al., 2008b; Nograles et al., 2008). These genomic maps
provide insights into the cellular sources of the gene-
expression signature and the complex positive and negative
feedback signaling pathways occurring between different
cell types. However, these model systems use monolayer
keratinocyte cultures and therefore may not fully recapitulate
the differentiated and multicellular environment present in
normal epidermis, uninvolved psoriatic skin, and psoriatic
plaques (PPs).
We have previously used the data set presented here to
explore the roles of the sonic hedgehog (Gudjonsson et al.,
2009a) and Wnt5a pathways in psoriasis (Gudjonsson et al.,
submitted). We have also studied the expression of genes
mapping to confirmed susceptibility loci in psoriasis (Nair
et al., 2009), as well as the profile of differential gene
expression comparing uninvolved psoriatic (PN) and normal
(NN) skin (Gudjonsson et al., 2009b). The aims of this study
were (i) to further delineate the gene expression profile of
lesional psoriatic (PP) relative to PN and NN skin in a large
data set; (ii) to compare our results with those reported in
previously published microarray studies of psoriasis; and (iii)
to explore how well the published transcript maps derived
from cytokine-stimulated cultured keratinocytes represent
the alterations observed in lesional psoriatic skin.
RESULTS
Alterations in gene expression in lesional psoriatic skin
Unsupervised principal-component analysis (Figure 1) of the
58 paired PP and PN and 64 NN samples showed near-
complete separation of the PN and NN samples from the PP
samples (Gudjonsson et al., 2009b). As described previously
(Zhou et al., 2003; Gudjonsson et al., 2009b), there was
substantial overlap between the PN and NN samples. These
results show a distinct gene expression profile of PP skin that
is markedly different from those of PN and NN skin. On the
basis of our criteria for differentially regulated transcripts (see
Materials and Methods), we identified 1,326 probes, encod-
ing 918 unique genes, that differed in expression between the
PP and NN samples (549 genes upregulated and 369 genes
downregulated), and 1,085 probes, detecting 758 unique
genes, between the PP and PN samples (Figure 2). There was
considerable overlap between the different groups of genes
(Figure 3). More genes were differentially expressed in the PP
versus NN skin than in the PP versus PN skin, suggesting that
the PN skin has subtle changes in the gene expression
pattern that make it more similar to PP skin than NN skin is
(see Supplementary File 1 online). The raw microarray
data of this study have been deposited in the NCBI Gene
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Figure 1. Hierarchical clustering of the entire data sample. This figure
has been presented previously (Gudjonsson et al., 2009b) and is presented
here for comparison. Unsupervised hierarchical clustering showed
near-complete separation of the PP (n¼58) samples from the PN and
NN samples, whereas there was some overlap between the PN (n¼58)
and NN (n¼ 64) samples (Gudjonsson et al., 2009b).
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Figure 2. Heatmap of differentially regulated transcripts between PP and
NN skin. Differentially regulated transcripts between PP and NN skin
(n¼1,326) are shown in a heatmap image. The blue color indicates low
expression levels whereas red indicates high expression levels. The black bar
above the heatmap indicates NN skin and the purple bar above the heatmap
indicates PP skin. Note that the number and intensity of upregulated
transcripts exceeds the number and intensity of downregulated transcripts.
Clustering was performed only on rows and based on row means, for column
samples were grouped into NN or PP groups without any clustering.
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Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo)
and is accessible through GEO Series accession number
GSE13355.
The most higly up- and downregulated genes
Several genes were increased more than 50-fold in PP as
compared with that in NN skin (Table 1A). These included
the peptidase inhibitors serpin peptidase inhibitor, clade-B,
member-4 (SERPINB4) and (SERPINB3), PI3, and the anti-
microbial peptide human b-defensin-2 (DEFB4). Other
upregulated genes included members of the S100 family of
proteins such as S100A7L1, S100A12, S100A9, and S100A7;
keratin-16; and IL-8. Only two genes showed more than
10-fold downregulation in PP skin: Wnt-inhibitory factor-1
(WIF1) and b-cellulin (BTC). Other notable downregulated
genes included thyroid hormone-responsive spot-14 (THRSP),
IL-1-family member-7 (IL1F7), and chemokine (C–C motif)
ligand-27 (CCL27) (Table 1B).
QRT–PCR confirmation of differentially regulated genes
We confirmed the up- and downregulation of several genes
in PP versus PN and NN skin by quantitative reverse trans-
cription–PCR (QRT–PCR). On average,DEFB4 and S100A7L1
(S100A7A) were upregulated more than 2,000- and 4,000-
fold in PP versus NN skin, respectively, whereas PI3 was
upregulated more than 1,300-fold, S100A12 about 63-fold,
small proline-rich-2C (SPRR2C) about 15-fold, and IL-8 about
150-fold (Figure 4). Likewise, we found that genes ELOVL3
and BTC were downregulated by 30-fold in PP versus
NN skin, whereas THRSP was downregulated by B8-fold
(Figure 4).
Comparison to previously published microarray studies
We compared our list of unique up- and downregulated
genes to those of Zhou et al. (2003), Oestreicher et al. (2001),
Nomura et al. (2003), and Haider et al. (2006) using the
same criteria of significance (42.0-fold change, Po0.05)
but removing duplicate genes, hypothetical transcripts, and
unnamed expressed sequence tags. Of the 549 unique
upregulated genes in our data sample, only 136 were present
in the data set of Zhou et al. (2003) (Supplementary Figure S1).
Likewise, of the 369 downregulated transcripts in our data
set, only 57 genes were found to be present in both data sets
(Supplementary File 2). Notable among the replicated
upregulated genes were RNASE7 (upregulated 3.1-fold,
P¼5.6E-24) and KLK8 (upregulated 2.5-fold, P¼7.8E-75).
Reproducibly downregulated genes included IL17D (down-
regulated 2.0-fold, P¼ 7.1E-23) and CD207 (encoding
langerin, downregulated 2.9-fold, P¼1.2E-29). Of the 159
genes that Oestreicher et al. (2001) identified in PP skin, 153
encoded unique genes. Of those, we could confirm the
expression of 49 in our data set (32%) (Supplementary
Figure S1). We also compared our data set to that of Nomura
et al. (2003). This study was limited to genes that were
differentially expressed between atopic dermatitis skin and
psoriatic skin. Of the 59 unique genes described we found 36
(61%) to be present in our upregulated gene list (data not
shown). Comparison to the results of Haider et al. (2006)
showed even greater overlap. This analysis was limited to
genes that were upregulated in both squamous cell carcino-
ma and psoriasis and were more than42-fold upregulated in
PP versus NN skin. Of the 102 unique genes that fulfilled
these criteria, 84 (82%) were present in our upregulated PP
versus PN and NN gene list (Supplementary File 2). Finally,
we compared our differentially expressed gene lists with
those of Yao et al. (2008). We found that among 721
upregulated probesets (PP vs PN) in our list, 666 (92.4%)
were present in that of Yao et al., and among 364
downregulated transcripts (PP vs PN), 323 (88.7%) were also
present in that of Yao et al.
Gene ontology and pathway analyses
Gene ontology analysis was focused on three major
categories, biological processes, cellular compartments, and
molecular function. As the gene expression profiles of PN and
NN skin are very similar (Gudjonsson et al., 2009b), we
compared the gene-expression signature of PP skin to that of
NN and PN skin combined to increase the statistical power.
For the upregulated genes the processes most significantly
enriched for upregulated transcripts in the combined
comparisons of PP versus NN and PP versus PN skin were
‘‘immune response’’, ‘‘defense response’’, and ‘‘response to
wounding’’ (Figure 5). Our analysis identified 90 upregulated
genes that were annotated with immune response (Figure 5),
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Figure 3. A Venn diagram of up- and downregulated genes in psoriasis skin.
The diagram shows a comparison of the overlap between PP versus NN, PP
versus PN, and PN versus NN genes for all up- and downregulated genes. Not
unexpectedly, there is a large overlap between the PP versus NN and PP
versus PN data sets. There was a larger overlap of PN versus NN with PP
versus NN (27 upregulated genes and 52 downregulated genes) as compared
with the PP versus PN (24 upregulated genes and 19 downregulated genes)
data set, suggesting that PN skin is more similar to PP skin.
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as compared with 25 genes in the largest previous analysis
of PP versus NN skin (Zhou et al., 2003). Despite the fact
that epidermal hyperproliferation and altered differentiation
are the most obvious histological features of psoriasis, the
P-value obtained for ‘‘immune response’’ was 6 orders
of magnitude more significant than that obtained for ‘‘mitotic
cell cycle’’; 9 orders of magnitude more significant than
that obtained for ‘‘ectodermal development’’; and 14 orders
of magnitude more significant than that obtained for ‘‘epi-
dermal cell differentiation’’. The main cellular compartments
involved included the extracellular space and the cornified
envelope. Chemokine and cytokine activity predominated
in the molecular function of the upregulated transcripts.
The downregulated categories involved biological processes
regulating fatty acid and lipid metabolism, organ develop-
ment, and blood circulation. Moreover, Ingenuity Pathway
Analysis identified ‘‘dendritic cell maturation’’ as the cano-
nical pathway most significantly and markedly enriched
within the differentially regulated transcripts, with 25 of
165 pathway components being differentially regulated
Table 1. The top 15 up- and downregulated genes in PP versus NN skin
Gene symbol Gene title
Fold
change
FDR
P-value
Mean in
control (log2)
Mean in
uninvolved (log2)
Mean in
lesional (log2)
(A) Upregulated PP versus NN
SERPINB4 Serpin peptidase inhibitor, clade-B, member-4 377 0 4.9 5.5 13.5
DEFB4 Defensin, b4 197 0 6.2 6.8 13.9
S100A7L1 S100 calcium-binding protein-A7-like-1 150 0 5.0 5.2 12.2
PI3 Peptidase inhibitor-3, skin-derived (SKALP) 131 0 6.5 7 13.5
SERPINB3 Serpin peptidase inhibitor, clade-B, member-3 64 0 7.0 7.4 13.0
SPRR2C Small proline-rich protein-2C 58 2.2E-264 4.4 4.6 10.3
AKR1B10 Aldo-keto reductase family-1, member-B10 58 0 5.9 6.4 11.8
S100A12 S100 calcium-binding protein-A12 (calgranulin-C) 57 0 4.7 4.9 10.6
S100A9 S100 calcium-binding protein-A9 (calgranulin-B) 57 0 8.7 9.3 14.5
C10orf99 Chromosome-10 open reading frame-99 32 0 6.0 6.9 11.4
KYNU Kynureninase (L-kynurenine hydrolase) 25 0 6.1 6.1 10.8
LCE3D Cornified envelope-3D 24 0 8.9 9.7 13.5
S100A7 S100 calcium-binding protein-A7 (psoriasin-1) 18 3.3E-114 9.9 10.7 14.1
IL-8 Interleukin-8 17 1.3E-53 4.3 4.4 8.4
KRT16 Keratin-16 17 5.7E-272 9.4 9.4 13.5
(B) Downregulated PP versus NN
WIF1 Wnt-inhibitory factor-1 14.0 4.5E-91 9.6 9.4 5.8
BTC b-Cellulin 13.9 5.6E-167 8.4 8.6 4.6
THRSP Thyroid hormone responsive spot-14 9.4 1.6E-24 11.1 10.5 7.9
IL1F7 Interleukin-1 family, member-7 (zeta) 8.4 3.5E-79 9.4 9.7 6.3
CCL27 Chemokine (C–C motif) ligand-27 7.7 7.5E-76 9.9 10.1 7.0
KRT1B Keratin-1B 7.6 4.9E-112 11.6 11.7 8.7
MSMB Microseminoprotein, b 6.5 2.4E-55 7.3 7.1 4.6
ELOVL3 Elongation of very long chain fatty acids-like-3 6.5 1.4E-18 8.9 8.0 6.2
GAL Galanin 6.4 1.1E-16 9.4 8.5 6.7
FABP7 Fatty acid binding protein 7, brain 6.0 1.7E-19 9.5 9.1 6.9
ACSBG1 Acyl-CoA synthetase bubblegum family member-1 5.7 3.8E-19 9.2 8.5 6.6
MLSTD1 Male sterility domain containing-1 5.2 9.8E-20 8.8 7.8 6.3
HS3ST6 Heparan sulfate (glucosamine) 3-O-sulfotransferase-6 4.2 2.9E-79 8.6 8.6 6.5
WDR72 WD repeat domain-72 4.2 5.3E-46 8.3 8.1 6.2
SERPINA12 Serpin peptidase inhibitor, member-12 4.1 1.5E-38 11.2 11.5 9.2
Abbreviations: FDR, false discovery rate; NN, non-psoriatic normal; PP, psoriatic plaque.
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(P¼1.3 108). Likewise, canonical pathways involving
LXR/RXR activation (Po1.0106), IL-10 signaling (Po1.0
105), pattern-recognition receptors (Po1.0 104), and IFN
signaling (Po1.0 104) were highly enriched (Supplementary
File 3). These results are in excellent agreement with those
reported in a previous gene ontology analysis of the psoriatic
transcriptome (Zhou et al., 2003).
Comparison to published cytokine-stimulated keratinocyte
transcriptomes
We compared the differentially regulated genes that we
found in PP skin versus PN and NN skin to previously
published data sets describing cytokine-induced gene expres-
sion changes in cultured keratinocytes (Banno et al., 2004;
Finelt et al., 2005; Bando et al., 2007; Mee et al., 2007;
Nograles et al., 2008). These published analyses were
focused on cytokines previously implicated in the patho-
genesis of psoriasis, including IL-1a (Mee et al., 2007),
oncostatin-M (OSM) (Finelt et al., 2005), TNF-a (Banno et al.,
2004), IFN-g (Mee et al., 2007), and the Th17 cytokines IL-22
and IL-17 (Nograles et al., 2008). For this analysis, we used
the same criteria for change that we used for the comparison
of PP skin versus PN and NN skin (42-fold change, Po0.05).
Several of the cytokine-induced transcripts observed in these
studies showed considerable overlap with that of the PP
transcriptome. Thus, IL-22 treatment caused upregulation
of four genes (S100A7, SERPINB4, S100P, SERPINB1) all
of which were also upregulated in the PP transcriptome
(Figure 6). Likewise there was substantial overlap between
IL-17-induced genes (Nograles et al., 2008) and lesional
gene expression, with 69% of IL-17-induced genes also
being significantly upregulated in the PP transcriptome. The
upregulated genes included DEFB4, the S100-family mem-
bers S100A7 and S100A12, and the chemokines CCL20,
CXCL1, CXCL3, and IL-8. The fold induction of these genes in
keratinocytes was commonly comparable to that observed in
PP skin. Thus, IL-17 treatment of keratinocytes induced the
expression of DEFB4 (238-fold), CXCL8 (14-fold), and CCL20
(28-fold), compared with 197, 17, and 7.8-fold, respectively,
in PP skin (Table 1). Interestingly, some of the genes were
induced more highly in keratinocyte cultures as compared
with that in PP skin. Thus, IL-22 and IL-17 stimulated S100A7
expression by a factor of 458 and 189, respectively (Nograles
et al., 2008), compared with 18-fold induction in PP skin,
possibly because basal levels of S100A7 are very low in
keratinocytes (Elder and Zhao, 2002) and the heterogenous
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Figure 4. QRT–PCR confirmation of several of the differentially expressed genes. PI3 (SKALP), DEFB4, S100A12, SPRR2C, and S100A7L1(S100A7A)
were upregulated 1,300; 2,200; 63; 15; and 4,500-fold, respectively, in PP versus NN skin, whereas ELOVL3, THRSP, and BTC were downregulated 30, 8,
and 36-fold, respectively, in PP skin. The results are shown relative to the expression of the housekeeping gene RPLP0 (36B4) and indicate the meanþ SEM;
n¼ 30. Statistical significance was tested using Student’s two-tailed t-test assuming equal variances and are indicated as **Po0.01 and ***Po0.001,
for PP versus PN skin.
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source of RNA in psoriatic lesional skin as compared with
these homogenous keratinocyte cultures could dilute the
keratinocyte-derived RNA fraction.
There was also considerable overlap between the expres-
sion of IFN-g-induced genes (Mee et al., 2007) and PP gene
expression. IFN-g induced the expression of several chemo-
kines such as CXCL9 and CXCL10 was that are found to be
increased in PP skin, but suppressed several genes involved in
cell proliferation that were upregulated in PP skin, including
the cyclin-A2, B1, and B2 (CCNA2, CCNB1, CCNB2,
respectively) and cell-cycle genes CDC2 and CDC20 (Mee
et al., 2007). These data are consistent with the observation
that IFN-g is one of the principal cytokines mediating the
growth-promoting effect of psoriatic T-cells (Bata-Csorgo
et al., 1995), even though it has a growth-suppressive effect
on cultured keratinocytes in monolayer cultures (Nickoloff
et al., 1984). Not surprisingly, there was also some overlap
between the expression of TNF-a-induced genes and PP gene
expression (Banno et al., 2004). TNF-a treatment of cultured
keratinocytes induced the expression of a number of
chemokines and cytokine receptors that are found to be
upregulated in PP skin, including IL-8 (CXCL8), CXCL1,
CXCL2, CCL20, IL1B, IL7R, and IL4R.
Although we found OSM mRNA to be elevated in PP skin
(1.3-fold, Po0.0001), there was minimal overlap between
genes upregulated in PP skin and genes induced by OSM in
keratinocyte monolayers (Finelt et al., 2005; Figure 6).
Interestingly, however, when epidermal constructs were used
instead of keratinocyte monolayer cultures, the number of
overlapping genes increased from 15 of 189 (7.9%) (Finelt
et al., 2005) to 50 of 279 (17.9%) (Gazel et al., 2006).
There was a much smaller overlap between downregu-
lated genes in cytokine-stimulated keratinocytes and that of
the PP downregulated transcriptome. Thus, only four of the
transcripts downregulated by IFN-g were also downregulated
GO categories for 
upregulated genes
Term
Immune response 90
Count %
13.91% 4.57E–20
1.00E–19
7.56E–19
7.08E–14
1.40E–11
6.28E–10
10.51%
8.81%
6.49%
4.17%
2.01%
P-value Term
Multicellular organismal
development
System development
Fatty acid metabolic process
Lipid metabolic process
Organ development
Blood circulation
Count
99 21.02% 4.94E–13
4.06E–11
4.66E–10
1.33E–08
2.16E–07
1.68E–06
16.56%
4.46%
8.92%
11.68%
3.40%
78
21
42
55
16
% P -value
Term Count
46 9.77%
5.10%
9.55%
24
45
30
190
39
% P-value
Term Count %
6.37%
40.34%
8.28%
P -value
1.88E–08
1.85E–06
1.35E–05
1.14E–08
2.18E–06
1.70E–04
Term
Extracellular space
Extracellular region part
Proteinaceous extracellular
matrix
Cytoskeletal protein binding
Protein binding
Structural molecule activity
Cytoskeleton
Spindle
Vesicular fraction
Microsome
Cornified envelope
Count
53
17
24
23
9
8.19% 4.95E–13
3.26E–09
2.07E–08
5.67E–08
1.05E–07
2.63%
3.71%
3.55%
1.39%
% P -value
Term
Chemokine activity
Chemokine receptor binding
Catalytic activity
Cytokine activity
Count
13 2.01%
2.01%
4.02%
38.02%
4.42E–08
5.58E–08
1.97E–07
7.36E–07
13
26
246
% P-value
68
57
42
27
13
Defense response
Response to wounding
Mitotic cell cycle
Ectoderm development
Keratinocyte differentiaion
GO categories for 
downregulated genes
Biological processBiological process
Cellular compartment
Cellular compartment
Molecular functionMolecular function
Figure 5. The enriched gene ontology categories for up- and downregulated transcripts.
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Figure 6. Comparison of the psoriatic transcriptome to cytokine-stimulated
keratinocytes. We compared the PP versus combined PN and NN
transcriptome to published genomic maps obtained from cytokine-stimulated
keratinocytes using the same criteria that was used for the PP transcriptome
(X2-fold change). This analysis was focused on cytokines previously
implicated in the pathogenesis of psoriasis, such as IL-1a (Mee et al., 2007),
OSM (Finelt et al., 2005), TNF-a (Banno et al., 2004), IFN-g (Mee et al.,
2007), IL-22, and IL-17 (Nograles et al., 2008). Note that there is no
overlap between the downregulated genes in PP versus NN/PN and IL-1a
downregulated genes. Several of the cytokines showed moderate overlap
with the psoriatic transcriptome, although this never represented more
than a very small fraction of the entire PP transcriptome (maximum 53 of
649¼ 5.6% for IFN-g).
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in PP skin, along with only four of the TNF-a-downregulated,
three of the IL-22-downregulated, three of the OSM-down-
regulated, and only two of the IL-17-downregulated genes
(Figure 6). As was observed for the corresponding upregu-
lated genes, the number of overlapping downregulated genes
in the OSM-stimulated skin equivalent model increased from
2% (3 out of 150) to 6.5% (14 out of 216) (Gazel et al., 2006)
(Supplementary File 4).
For several of the cytokines, there was an overlap between
the downregulated genes in treated keratinocytes and upregu-
lated genes in PP skin. Thus, for IFN-g, out of 96 down-
regulated genes, 23 were present on the PP upregulated gene
list. Similarly, for OSM-treated keratinocyte monolayers
(Gazel et al., 2006), out of 150 downregulated genes, 19
were present on the PP upregulated gene list. Reminiscent
of the effects of IFN-g on cultured keratinocytes (Nickoloff
et al., 1984), many of these genes encoded cyclins (CCNA2,
CCNB1) and other components involved in cell-cycle
regulation such as CDC2, CDC20, and CDKN3. Whereas
there are no reports of the effects of OSM on the proliferation
of monolayer keratinocytes, it has been shown to induce
migration of monolayer keratinocytes and induce hyperplasia
of keratinocytes in reconstituted human epidermis (Boniface
et al., 2007).
DISCUSSION
This is the largest study of global gene expression in psoriasis to
date and provides a global view of the biological changes that
occur in lesional skin. Many of the changes that we observed
are confirmatory of previous observations (Oestreicher et al.,
2001; Zhou et al., 2003; Yao et al., 2008), but the data
presented here expand these in scope and detail and provide a
greater in-depth insight into the biological changes that occur
in psoriatic lesions.
Several factors could be responsible for the somewhat
limited overlap between our study and these other studies.
The first of these is study design. In the work of Nomura
et al. (2003) the aim was to compare the gene expression
of psoriasis with that of atopic dermatitis, whereas in that
of Haider et al. (2006), the PP transcriptome was compared
to that of squamous cell carcinoma. Second, the larger
sample size of this study provides increased power to identify
differentially regulated genes. Third, these studies were
performed using different microarray platforms, representing
overlapping but non-identical visualizations of the human
transcriptome, although there is greater overlap with the
more recent arrays possibly reflecting a larger number of
probesets that these assays have in common. Thus, several of
the genes reported by Zhou et al. represented expressed
sequence tags and hypothetical genes that are no longer
annotated as genes on the microarray that we used. More-
over, several of the genes reported by Zhou et al. later were
shown to be different probes targeting the same genes,
leading to overestimation of the number of genes involved.
One other cause of discrepancy between the data sets is
batch effect (Akey et al., 2007). In comparing our data set to
that of Yao et al. (2008) we noted that pairs of non-lesional/
lesional skin samples were not always processed together at
the same time, therefore creating a batch effect inflating the
number of differentially expressed genes. We avoided this
confounding effect by running the paired uninvolved and
lesional samples at the same time. Overall, most of our
differentially expressed transcripts were present in the data
set of Yao et al. indicating that the data of Yao et al. included
truly differentially expressed genes along with those ‘‘noisy’’
genes that were introduced due to the batch effect in the data.
One of the canonical pathways that was upregulated in
our data set involved members of the IFN-signaling pathway,
with 8 of 29 pathway components upregulated. The IFNs
consist of two classes: type-I, which includes IFN-a and IFN-b,
which have an important role in antiviral defenses and are
almost exclusively derived from plasmacytoid dendritic cells,
and type-II, which includes IFN-g, which is the prototypical
Th1 cytokine. Subcutaneous injection of IFN-g has been
shown to induce localized psoriasis in the uninvolved skin of
psoriatic patients (Fierlbeck et al., 1990). More recently,
plasmacytoid-derived type-I IFNs where shown to have a
central role in the onset of psoriatic lesions in a spontaneous
xenograft model of psoriasis (Nestle et al., 2005). Consistent
with previously published studies (Nestle et al., 2005) we
could not detect upregulation of type-I IFNs in established
chronic plaque lesions. However, the type-II IFN, IFNG, was
upregulated 1.4-fold. The most strongly upregulated genes
belonging to the IFN-signaling pathway were STAT1 (2.8-fold),
MX1 (4.5-fold), IRF1 (2.0-fold), IRF9 (2.1-fold), andOAS1 (4.4-
fold). Moreover, at least 40 other IFN-inducible transcripts
were upregulated at least two-fold in PP versus NN skin,
including OASL (9.9-fold), OAS2 (9.0-fold), RGS1 (7.0-fold),
IFI27 (8.0-fold), CXCL10 (7.1-fold), PBEF1 (5.3-fold), IFI6 (5.0-
fold), and CXCL1 (5.8-fold). These results confirm and extend
the results of earlier studies indicative of a strong IFN-response
signature in psoriasis (Zhou et al., 2003; Lew et al., 2004; Yao
et al., 2008). Besides activating IFN signature genes, IFN-g can
influence other cytokine pathways. We have recently shown
that IFN-g produced by T-cells is a major stimulus for the
production of IL-23 by macrophages or dendritic cells
(Kryczek et al., 2008), which in turn stimulates the develop-
ment of Th17 cells (Harrington et al., 2005; Kryczek et al.,
2008).
Several lines of evidence indicate that TNF-a also has a
central role in the pathogenesis of psoriasis. Treatments that
block the action of TNF-a have profound therapeutic effects
on psoriasis (Lowes et al., 2007), and polymorphisms of two
variants that regulate TNF-a signaling were recently identified
in a genome-wide association study of subjects with psoriasis
and point to a possible altered NF-kB-signaling pathway in
psoriasis (Nair et al., 2009). The predominant source of
TNF-a in psoriatic skin is activated dendritic cells (Boyman
et al., 2004), and whereas TNF-a mRNA was only increased
by 1.3-fold in PP versus NN skin, several genes known to be
upregulated by TNF-a treatment were markedly induced,
including AKR1B10 (aldose reductase, 57.6-fold; Iwata et al.,
1999), IL1F9 (IL-1e, 36.3-fold; Debets et al., 2001), MMP12
(macrophage elastase, 9.1-fold; Feinberg et al., 2000), CCL20
(MIP-3a (7.8-fold), IL1F5 (6.6-fold); Debets et al., 2001), and
CXCL9 (MIG, 6.1-fold; Rottman et al., 2001). TNF-a has
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recently been shown to have a role in maintaining the
Th17 subset of T-cells in psoriatic skin (Zaba et al., 2007) and
may synergize with IFN-g in the induction of proinflamma-
tory mediators from mononuclear leukocytes (Haider et al.,
2008a). Thus, there is a strong synergy between TNF-a and
IFN-g signaling in the course of T-cell activation by dendritic
cells, as has been found for a variety of cell types (Boehm
et al., 1997).
As mentioned earlier, the newly identified T-cell subset
Th17 has recently been implicated in the pathogenesis of
psoriasis and other disease involving epithelial barriers
(Bettelli et al., 2006; Zaba et al., 2007). Although the
transcripts directing the synthesis of IL-12 and IL-23 did not
reach the threshold of twofold change, this likely being due to
the low sensitivity of microarrays for less abundantly
expressed transcripts, we found highly significant changes
(Po1010) in IL12B (p40), being upregulated 1.2-fold, and
IL23A (p19), upregulated 1.2-fold, but no change in expres-
sion for IL12A (p35). IL-17 strongly induces the expression of
several chemokines by keratinocytes, including CXCL1,
CXCL3, CXCL5, CXCL6, CXCL8 (IL8), and CCL20 (Nograles
et al., 2008), and also induces the expression of antimicrobial
peptides such as DEFB4 (Wilson et al., 2007). Of the 47 genes
that were found to be upregulated in keratinocytes by IL-17
(Nograles et al., 2008), we could confirm 36 to be upregu-
lated in lesional skin, although several of these had a less than
twofold change as seen by microarray analysis. More-
over, IL-17 suppresses TNF-a-induced CCL27 production
by keratinocytes (Kanda et al., 2005); in agreement with
previously published data (Nomura et al., 2003) CCL27 is
among the most markedly downregulated transcripts in PP
skin (Table 1). In contrast to IL-17, IL-22 is a relatively weak
inducer of chemokine expression in keratinocytes, but has
more marked effect on the differentiation and proliferation of
stratified epithelium and the expression of antimicrobial
proteins such as the S100 family of proteins (Wolk et al.,
2006; Sa et al., 2007). Of the 21 unique genes induced or
suppressed in keratinocytes by IL-22 (Nograles et al., 2008),
17 were found to be similarly changed in PP skin. The high
expression of antimicrobial peptides is characteristic for
psoriasis; this is in contrast to atopic dermatitis, which despite
comparable epidermal proliferation, is not characterized
by a similar overexpression of these genes (de Jongh et al.,
2005; Buchau and Gallo, 2007). Many of the most highly
upregulated transcripts we have identified in psoriasis encode
antimicrobial peptides, including DEFB4 (197-fold), S100A7
(18-fold), S100A8 (12-fold), S100A9 (57-fold), S100A12
(57-fold), S100A7L1 (also known as S100A15 and is now
officially designated S100A7A) (150-fold), and LCN2
(17-fold) (Table 1).
Despite being limited by the lack of many of the cellular
players in psoriasis, including inflammatory cells, fibroblasts,
and endothelial cells, keratinocyte cultures have been used
as a models to gain insights into cytokine-driven gene
expression changes in psoriatic skin either using keratino-
cytes in monolayer or as epidermal constructs. These
cytokines include IL-1 (Mee et al., 2006; Yano et al., 2008),
OSM (Finelt et al., 2005; Boniface et al., 2007), TNF-a
(Banno et al., 2004, 2005), and IFN-g (Banno et al., 2003;
Mee et al., 2006, 2007). Whereas treatment with either IL-1
or OSM upregulated several of the most strongly upregulated
transcripts observed in PP skin, including SERPINB4, DEFB4,
IL1F9, PI3, S100A7, S100A8, S100A9, and S100A12, other
strongly upregulated transcripts, such as CXCL9 and CXCL10
were not upregulated; rather, these transcripts were strongly
induced by IFN-g. Conversely, several transcripts that were
strongly induced in culture were not strongly upregulated
in psoriasis. Although some of this discrepancy is influenced
by the heterogenous mixture of cells involved in lesional
psoriatic skin as compared with the homogenous keratino-
cyte cultures, it is likely that the psoriatic transcriptome
reflects exposure of the epidermis to a medley of multiple
cytokines, producing a response that can be partially but not
completely mimicked by any single cytokine alone as was
recently shown in a novel skin-equivalent system (Tjabringa
et al., 2008). Likewise, it appears that the model system used
has important implications for the gene expression pattern
observed. This is clearly shown by the OSM studies (Finelt
et al., 2005; Gazel et al., 2006) where the overlap between
gene-expression signature and PP skin increased from 7.9 to
17.9% by using reconstituted epidermal constructs instead of
semi-confluent keratinocyte cultures. Finally, one study
examined a panel of 33 cytokines singly and in various
combinations, and found that IL-1a and IL-1b, IL-6, IL-17,
IL-20, IL-22, IL-24, and TNF-a could provoke S100A7 and
DEFB4 responses similar to that elicited by OSM. They also
observed marked synergy between IL-17, TNF-a, and OSM as
the major inducers of S100A7 and DEFB4 (Boniface et al.,
2007).
Many of the most highly upregulated genes that we
encountered reside in the epidermal differentiation complex
located on chromosomal band 1q21. In addition to the S100
genes involved in the innate immune response, these include
the SPRR and the late cornified envelope gene families whose
members have important roles keratinocyte terminal differ-
entiation (Gibbs et al., 1993; Eckert et al., 2004; Jackson
et al., 2005). These gene families are structurally distinct and
rapidly evolving (Ravasi et al., 2004; Jackson et al., 2005),
suggesting that this distinctive chromosomal region is under
some form of long-range epigenetic regulation (Segre, 2006).
Other clustered and highly upregulated genes encode the
serine peptidase inhibitors SERPINB3 (upregulated 64-fold),
SERPINB4 (upregulated 377-fold), and SERPINB13 (upregu-
lated 7.5-fold) on chromosome 18q21.3, and the kallikrein
serine proteases KLK6 (upregulated 9.2-fold) and KLK13
(upregulated 9.8-fold) on chromosome 19q13. The mechan-
ism(s) through which these clustered genes are coordinately
upregulated in psoriasis remain to be determined.
Psoriasis is characterized by a markedly altered balance
of proteolytic and antiproteolytic activities involved in
keratinocyte turnover (Magert et al., 2005), consistent with
the observation that catalytic activity was one of the most
highly upregulated molecular functions upregulated in PP
skin (Figure 5). In addition to the clustered proteases
and inhibitors described above, the PI3 gene (upregulated
131-fold) encoding protease inhibitor-3 (SKALP/elafin) is
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markedly overexpressed in psoriasis (Alkemade et al., 1994).
Several of these proteases were stimulated by cytokines in
keratinocyte cultures, particularly PI3 and members of
SERPINB. Thus, IL-1a, IL-17, and IL-22 induced the expres-
sion of SERPINB4 (Bando et al., 2007; Nograles et al., 2008)
in keratinocytes. OSM, IFN-g, and TNF-a increased the
expression of SERPINB1 (Banno et al., 2004; Finelt et al.,
2005; Mee et al., 2007), and IL-1a-induced the expression of
SERPINB3 and PI3 (Bando et al., 2007), whereas TNF-a
induced SERPINB8 expression (Banno et al., 2004). Interest-
ingly, OSM’s stimulation of reconstituted epidermal con-
structs greatly increased the number of proteases and
protease inhibitors overlapping with that of PP skin (KLK13,
PI3, SERPINB1, SERPINB4, SERPINA1, and SERPINA3)
(Gazel et al., 2006). In all instances the expression observed
in keratinocytes or reconstituted epidermis was lower than
that observed in PP skin. This indicates that expression
of proteases and protease inhibitors is rather a function of the
stratified epithelia in contrast to keratinocyte monolayer
cultures. Furthermore, the dramatic overexpression of these
proteases and antiproteases shows that control of the
proteolytic environment is a crucial element of epidermal
homeostasis and barrier function (Meyer-Hoffert, 2009).
Interestingly we observed large alterations in genes
involved in metabolism, particularly lipid and fatty acid
metabolism (Figure 5), and amino-acid metabolism (Supple-
mentary File 3). Kynureninase (KYNU) is one of the genes
that was among the most highly upregulated genes in
psoriatic skin in our data set (Table 1). Upregulation of
KYNU has been reported previously in psoriasis (Nomura
et al., 2003; Ito et al., 2004) as well as atopic dermatitis (Ito
et al., 2004). The product of this gene is involved in
tryptophan metabolism and 11 other genes involved in the
tryptophan pathway were found to be differentially regulated
in psoriatic skin (Supplementary File 3). Importantly, activity
of this pathway is induced by IFN-g (Taylor and Feng, 1991;
Ito et al., 2004). The exact role of this pathway in psoriasis is
unknown, but upregulation of tryptophan catabolism has
been shown to confer antibacterial effector functions on
multiple cell types, including epithelial cells (Daubener and
MacKenzie, 1999). The changes we observed for genes
involved in lipid and fatty acid metabolism are similar to
changes that we have previously reported in uninvolved and
lesional psoriatic skin, and suggests an defect involving the
lipid barrier of the epidermis of psoriatic skin (Gudjonsson
et al., 2009b).
Taken together, these results are broadly consistent with
the model for development and maintenance of psoriatic
lesions that has emerged in recent years. Thus complex two-
way interactions between activated dendritic cells, T-cells,
and keratinocytes, are largely mediated by cytokines and
chemokines, and punctuated by periodic bursts of neutro-
philic infiltration of the epidermis (Lowes et al., 2007).
Interestingly, several of the most highly upregulated genes in
PP skin drive neutrophil infiltrations, including IL-8 (CXCL8)
(upregulated 17 fold vs NN) and CXCL1 (upregulated 5.8-fold
vs NN). However, neutrophils appear to be dispensable
for the development of psoriasis in a transgenic mouse
model (Stratis et al., 2006), focusing attention on mono-
nuclear cells.
We observed fewer downregulated than upregulated
transcripts in PP skin, compared with that in either PN or
NN skin. Of the downregulated transcripts observed in PP
skin (Table 1) WIF1, encoding Wnt-inhibitory factor-1, and
BTC, encoding BTC, were the most prominent. WIF-1 is a
secreted protein that binds to Wnt proteins and inhibits their
activities (Hsieh et al., 1999). Taken together with increased
expression of the non-canonical Wnt member, WNT5A, that
we and others (Zhou et al., 2003; Reischl et al., 2007) have
observed, we have proposed that the non-canonical Wnt
pathway may be activated in psoriasis (Gudjonsson et al.,
submitted). BTC is one of several epidermal growth factor
(EGF)-receptor ligands expressed in the skin, along with
amphiregulin, heparin-binding EGF, transforming growth
factor-a, and epiregulin. In contrast to the other EGF-family
ligands, many of which have been reported to be upregulated
(Elder et al., 1989; Shirakata et al., 2007), BTC is down-
regulated in psoriasis, as shown by immunohistochemistry
(Piepkorn, 1996; Piepkorn et al., 2003) and by a previous
microarray analysis (Zhou et al., 2003). These results suggest
that BTC may have a role in the maintenance of the
differentiated phenotype of the epidermis (Piepkorn et al.,
2003). In addition to CCL27 discussed earlier, interesting
transcripts that were markedly downregulated in PP versus
NN skin included THRSP, encoding a nuclear protein
involved in fatty acid synthesis (Cunningham et al., 1998),
GAL, encoding galanin, a vasoactive peptide that mediates
vasoconstriction and inhibition of blood flow (Schmidhuber
et al., 2007), IL1F7, which has been shown to be expressed in
fully differentiated keratinocytes in the stratum granulosum of
the epidermis (Busfield et al., 2000), and MSH5, thought to
participate in mitotic DNA repair (Her et al., 2007). There
was very small overlap between genes downregulated by
individual cytokines and those downregulated in PP skin.
Interestingly, this overlap was larger for the only study of
cytokine-stimulated reconstituted epidermis (Gazel et al.,
2006) published so far. In that study one of the transcripts that
was downregulated, encoded for BTC, which is a member of
the EGF ligand family and one of the most strongly down-
regulated transcripts in PP skin, but its expression is undetect-
able in keratinocyte monolayers (Johnston, unpublished
observation). Thus, apart from the more complex situation
in PP skin where various combinations and two-way
interactions of cytokines and activated immune cells may
affect gene expression, this indicates that lack of stratification
may be one of the reasons for the small overlap observed
between downregulated genes in PP skin and that of cytokine-
stimulated keratinocyte monolayers. Finally, another explana-
tion for this discrepancy may relate to differences in epidermal
and keratinocyte responses between psoriasis and healthy
controls that have been proposed to be genetically determined
(Zeeuwen et al., 2008).
In conclusion, this is the most comprehensive analysis of
differentially regulated transcripts in psoriasis and provides
a global view of the psoriatic transcriptome. This study
identified group of genes that are dysregulated in lesional
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psoriatic skin, large proportion of which have not been
described before. Our comparison of the PP transcriptional
genome and the limited overlap with genomic maps obtained
from previously published cytokine-stimulated keratinocytes
using monolayer systems indicates the limitations of using
this approach and suggests that greater insights into the
pathogenesis of psoriasis and the effect of individual key
cytokines might be obtained by using reconstituted epidermal
constructs or other more elaborate tissue models. Overall,
these data provide novel insights into the pathogenic
mechanisms involved in psoriasis and more accurately define
the biochemical changes and pathways involved.
MATERIALS AND METHODS
Subjects
The criterion for entry of a case was the presence of at least one well
demarcated, erythematous, scaly PP that was not limited to the
scalp. In those instances where there was only a single PP, the case
was only considered if the plaque occupied more than 1% of the
total body surface area. We enrolled 58 patients with psoriasis and
64 normal healthy controls to the study. This study was approved by
the Institutional Review Board of the University of Michigan Medical
School and was conducted according to the Declaration of Helsinki
Principles. Informed written consent was obtained from all study
subjects. Study subjects did not use any systemic anti-psoriatic
treatments for 2 weeks before topical anti-psoriatic treatments for
1 week before biopsy. Two biopsies were taken under local
anesthesia from each psoriatic subject; one 6-mm punch biopsy
was obtained from PP skin and the other from PN skin sampled at
least 10 cm away from any active plaque. One or two biopsies were
obtained from the normal skin of healthy controls (NN skin). Gender
was balanced in both case and control cohorts. The mean age of
the controls was 41.1 years (range 18–75), whereas the mean age
of the cases was 48.5 years (range 21–69). Patients’ demographic
characteristics are shown in Supplementary File 5.
RNA processing and microarray hybridization
After removal from the skin, biopsies were snap-frozen in liquid
nitrogen and stored at 80 1C until use. Biopsies were pulverized
with a hammer while still frozen and total RNA isolation was
performed using a commercial kit (RNeasy, Qiagen, Chatsworth,
CA), using glass beads (Biospec, Bartleville, OK) for homogeniza-
tion. RNA quantity and quality were measured using an Agilent
2,100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Only
samples yielding intact 18S and 28S ribosomal RNA profiles were
used. cDNA and in vitro transcription for probe biotinylation were
performed using 5 mg of total RNA according to the manufacturer’s
protocols (Affymetrix, Foster City, CA). Samples were run on HU133
Plus 2.0 arrays to query the expression of 454,000 probes.
Quantitative reverse transcription–PCR
Reverse transcription reaction was performed using 0.15mg of RNA
template and cDNA was synthesized using a High Capacity cDNA
Reverse Transcription kit as per manufacturer’s protocols (Applied
Biosystems, Foster City, CA). The primers for genes IL-8, DEFB4,
S100A7A, S100A12, PI3, THRSP, ELOVL3, and BTC were obtained
from Applied Biosystems. Results were normalized to the expression of
the housekeeping gene RPLP0/36B4, encoding ribosomal protein, large,
P0 (Minner and Poumay, 2009). QRT–PCR was performed using an
Applied Biosystems 7900HT Fast Real Time PCR System. Fold changes
were calculated comparing normal versus lesional psoriatic skin.
Microarray data analysis and statistics
The Robust Multichip Average (RMA) method (Irizarry et al., 2003)
was used to process the raw data from 180 microarrays. The data
were adjusted to account for gender and batch effects. Specifically,
we used a linear regression model to estimate the gender and batch
effects, and then subtracted them from the RMA expression values to
obtain the adjusted data. Hierarchical clustering (using a ‘‘com-
plete’’ agglomeration method) and principal-component analysis
were performed using the adjusted expression data using the
publicly available software R (www.r-project.org). Gene expression
was contrasted between PP versus PN (by using one-sample t-tests
on the difference between paired PP, PN samples) or PN versus NN
(by using two-sample t-tests) on the basis of the following criteria:
X2.0-fold change in the means of expression in the two groups and
a false discovery rate P-valuep0.05. Transcripts with small variation
across samples were not filtered out. But when the estimated
variance for a gene in the t-test was less than the median variance for
all genes, we used the median variance in the t-test. In doing so, we
prevented genes from being designated differentially expressed if they
had very small variation. Gene ontology category enrichment analysis
was performed using DAVID (Database for Annotation, Visualization
and Integrated Discovery; http://david.abcc.ncifcrf.gov/; Bethesda,
MD). For this exploratory analysis, P¼ 0.001 was chosen as a
stringent significance criterion and P¼ 0.05 as a relaxed significance
criterion. QRT–PCR data were tested for significance using Student’s
two-tailed t-test assuming equal variances and P-values p0.05 were
considered to be significant.
Ingenuity pathway analysis
The Ingenuity Pathway Analysis software package (Ingenuity Systems,
Redwood City, CA) was used to analyze the differentially regulated
transcripts. For network and pathway generation, a data set containing
gene identifiers and the corresponding expression values was uploaded
into the application. Each gene identifier was mapped to its
corresponding gene object in the Ingenuity pathways knowledge base.
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